Source comparison
TB-500 Vial Size Comparison: Doses Per Container by Protocol Type
The table below shows how many doses vial TB-500 provides across common vial sizes and protocol phases. Reconstitution volumes are optimized for syringe precision (0.01mL resolution) and subcutaneous injection comfort (≤1mL per administration). 5mg 2mL 2.5mg/m
This comparison does not assign a generated winner or score.
- The table below shows how many doses vial TB-500 provides across common vial sizes and protocol phases. Reconstitution volumes are optimized for syringe precision (0.01mL resolution) and subcutaneous injection comfort (≤1mL per administration).
- 5mg
- 2mL
- 2.5mg/mL
- 2 doses
- 5 doses
- 10 doses
- Best for short-term single-subject studies or maintenance-only protocols
- 10mg
- 4mL
- 4 doses
- 20 doses
- Optimal for standard 4-week loading protocols with 2 administrations/week
- 20mg
- 8mL
- 8 doses
- 40 doses
- Preferred for multi-subject studies or extended maintenance phases beyond 12 weeks
- 5mL
- 1mg/mL
- Not recommended (requires 2.5mL per dose)
- Dilute concentration suitable only for maintenance dosing
- Loading phase dose counts assume 2.5mg per administration—the midpoint of the 2–5mg range observed in musculoskeletal repair research. Protocols using 5mg per dose cut these counts in half. Maintenance phase assumes weekly or biweekly administration schedules; daily micro-dosing protocols (200–500mcg/day) consume vials 5–7× faster without proportional benefit in most injury models.